Three patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Aug 2029
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2010 to 2031.
US 9,029,607
Protected Aldehydes For Use As Intermediates In Chemical Syntheses, And Processes For Their Preparation
Jul 22, 2031
201420182022202620302031
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2031 · High confidence
Also notable
Ends Aug 2029 · Medium confidence
Also notable
Ends no later than Sep 2029 · Medium confidence
Protected Aldehydes For Use As Intermediates In Chemical Syntheses, And Processes For Their Preparation
US 9,029,607
The most cited patent in this portfolio, cited by 18 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2031.
Ready-To-Use Bivalirudin Compositions
US 7,803,762
Renewed at every maintenance window since the 2010 grant; no more fees are due before its term ends in 2029. A terminal disclaimer caps this term to an earlier patent's.
Ready-To-Use Bivalirudin Compositions
US 7,713,928
Renewed at every maintenance window since the 2010 grant; no more fees are due before its term ends in 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Protected Aldehydes For Use As Intermediates In Chemical Syntheses, And Processes For Their Preparation | 1 in force | to Jul 2031 |
| Ready-To-Use Bivalirudin Compositions | 1 in force | to Aug 2029 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,803,762 | Ready-To-Use Bivalirudin Compositions In force · Medium confidence | In force | Medium confidence | |
| US 7,713,928 | Ready-To-Use Bivalirudin Compositions In force · Medium confidence | In force | Medium confidence | |
| US 9,029,607 | Protected Aldehydes For Use As Intermediates In Chemical Syntheses, And Processes For Their Preparation In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 3 patents ended · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed